

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

Jynarque (tolvaptan)

Criteria:

- **Criteria for initial therapy:** Jynarque (tolvaptan) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Nephrologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD) who is at risk for rapidly progressing kidney dysfunction
 4. Individual has **ONE** of the following risks for progression to end-stage renal disease:
 - a. Mayo Clinic classes 1C, 1D, or 1E (a measurement of total kidney volume (TKV) growth)
 - b. Bilateral TKV \geq 750 mL (by magnetic resonance imaging [MRI], or computed tomography [CT])
 - c. Bilateral kidney length > 16.5 cm (by ultrasound, MRI, or CT)
 - d. PROPKD score > 6
 5. Individual has failure, contraindication or intolerance to angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
 6. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
 - a. Measure ALT, AST, bilirubin as required by the Jynarque REMS Program
 - b. Comprehensive metabolic panel
 - c. Correction of any abnormalities of serum sodium
 - d. Blood pressure
 7. There are **NO** contraindications
 - a. Contraindications include:
 - i. With a history, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease
 - ii. Concurrent use with strong CYP 3A inhibitors
 - iii. Use in uncorrected abnormal blood sodium concentrations
 - iv. Individual is unable to sense or appropriately respond to thirst
 - v. Individual with hypovolemia
 - vi. Hypersensitivity (e.g., anaphylaxis, rash) to tolvaptan or any component of the product
 - vii. Uncorrected urinary outflow obstruction
 - viii. Anuria
 8. Will not be used with CYP3A inducers such as barbiturates, carbamazepine, phenytoin, rifabutin, rifampin, rifapentin, St. John's wort

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral SAMSCA® (tolvaptan) oral Tolvaptan oral

9. Will not be used with desmopressin or vasopressin or Samsca (tolvaptan) or Vaprisol (conivaptin)
10. Will not be used in individuals with a creatinine clearance of less than 25 mL/min

Initial approval duration: 3 months

- **Criteria for continuation of coverage (renewal request):** Jynarque (tolvaptan) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Nephrologist
 2. Individual's condition responded while on therapy
 - a. Response is defined as:
 - i. Achieved and maintains **TWO** of the following:
 1. Blood pressure is < 130/80
 2. At least a 25% improvement on serum creatinine from baseline
 3. No albuminuria
 4. Reduction in kidney pain
 5. Reduction in kidney volume
 3. Individual has been adherent with the medication
 4. There are no significant interacting drugs
 5. Will not be used in individuals with a creatinine clearance of less than 25 mL/min
 6. Will not be used with desmopressin or vasopressin or Samsca (tolvaptan) or Vaprisol (conivaptin)

Renewal duration: 12 months

Samsca (tolvaptan) Tolvaptan

Criteria:

- **Criteria for therapy:** Samsca (tolvaptan) and Tolvatpan are considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Nephrologist, Cardiologist, or Endocrinologist

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

2. Individual is 18 years of age or older
3. Therapy is initiated **OR** re-initiated in a hospital setting **AND/OR** individual is pending hospital discharge **AND** individual has not already received 30 days of tolvaptan therapy from a recent previous hospitalization
4. A confirmed diagnosis of clinically significant hypervolemic **OR** euvolemic hyponatremia as evidenced by **ONE** of the following:
 - a. Serum sodium prior to initiation is < 125 mEq/L
 - b. Serum sodium prior to initiation is 125-134 mEq/L **and** individual is symptomatic for hyponatremia (e.g., nausea, vomiting, headache, lethargy, confusion, etc.)
5. Individual has failure, contraindication or intolerance such that the individual is unable to use therapies to control hyponatremia, such as:
 - a. Fluid restriction
 - b. Loop diuretics
 - c. Demeclocycline
 - d. Saline infusion
6. For Samsca: Individual has failure, intolerance, or contraindication to use of generic tolvaptan
7. Drug-induced causes of hyponatremia have been discontinued
8. There are **NO** contraindications:
 - a. Contraindications include:
 - i. Use in patients with autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS
 - ii. Need to raise serum sodium acutely or urgently
 - iii. Individual is unable to sense or appropriately respond to thirst
 - iv. Hypovolemic hyponatremia
 - v. An individual who is anuric
 - vi. Use with strong CYP3A inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, nefazodone
 - vii. Hypersensitivity (anaphylactic shock, generalized rash) to tolvaptan or any component of the product
9. Will not be used with CYP3A inducers such as barbiturates, carbamazepine, phenytoin, rifabutin, rifampin, rifapentin, St. John's wort
10. Will not be used in patients with underlying liver disease, including cirrhosis
11. Will not be used with desmopressin or vasopressin or Jynarque (tolvaptan) or Vaprisol (conivaptin)
12. Will not be used in individuals with a creatinine clearance of less than 10 mL/min

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

Approval duration:

Total of 30 days only including the number of days while inpatient
No renewal or continuation beyond 30 days

Description:

Samsca (tolvaptan) is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with Samsca (tolvaptan). It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients. Hyponatremia may present with nausea, headache, lethargy, muscle cramps, altered gait or falls, mental status changes, seizures, or coma.

Jynarque (tolvaptan) is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

Samsca (tolvaptan) should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., > 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.

Arterial vasodilatation is involved in the development of hyponatremia. With arterial vasodilatation there is a reduction in the effective arterial blood volume, this in turn leads to the stimulation of several neurohumoral systems [the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS)] and the non-osmotic release of an antidiuretic hormone, arginine vasopressin (AVP or vasopressin). The activation of the RAAS and SNS results in sodium retention and renal vasoconstriction. Increased levels of AVP causes activation of vasopressin 2 (V2) receptors within the renal tubules. These receptors play a major role in the rate of solute-free water excretion. Depending on the daily water intake, patients cannot excrete enough free water and they develop water retention, which generates serum dilution and hypo-osmolality.

Hyponatremia can be hypovolemic, euvolemic (normovolemic), or hypervolemic. Hypovolemic hyponatremia is a result of fluid losses either from the kidneys (most commonly due to iatrogenic over-diuresis) or loss from the gastrointestinal tract (such as diarrhea). Patients typically will have signs of dehydration and findings of pre-renal azotemia due to the contraction of the total plasma volume. Patients with hypovolemic hyponatremia should be treated with the withdrawal of diuretics and the infusion of isotonic solutions to normalize the total body sodium level.

In euvolemic hyponatremia the total body sodium level is normal or near normal. Asymptomatic patients need only have their free water restricted.

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral SAMSCA® (tolvaptan) oral Tolvaptan oral

Hypervolemic hyponatremia is characterized by a pronounced deficit of free water excretion and leads to inappropriate water retention in comparison with the sodium concentration. This imbalance results in an expanded extracellular volume and dilutional hyponatremia. Patients with hypervolemic hyponatremia usually have ascites and/or edema and may have concurrent kidney injury. Hypervolemic hyponatremia should be managed by restricting free water ingestion, by increasing renal excretion of solute-free water, and by correcting the vasodilatation and the resultant decreased effective arterial blood volume. Causes of this type of hyponatremia include congestive heart failure, liver cirrhosis, and renal diseases such as renal failure and nephrotic syndrome.

Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native AVP. Tolvaptan affinity for the V2-receptor is 29 times greater than that for the V1a-receptor. When taken orally, 15-60 mg doses of tolvaptan antagonize the effect of AVP and cause an increase in urine water excretion that results in an increase in free water clearance (so called aquaresis), a decrease in urine osmolality, and a resulting increase in serum sodium concentrations. Urinary excretion of sodium and potassium and plasma potassium concentration are not significantly changed. Doses above 60 mg do not increase aquaresis or serum sodium further.

Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous fluid filled cysts in both kidneys. The progressive expansion of cysts occurs slowly which replaces much of the normal mass of the kidneys, reducing kidney function and ultimately leading to kidney failure. Cysts may also develop in other organs such as the liver, pancreas, spleen, heart, and blood vessels of the brain. ADPKD patients suffer from acute or chronic pains (mostly caused by infection or intracystic bleeding), hematuria, urinary tract infections, nephrolithiasis and hypertension.

Autosomal dominant polycystic kidney disease (ADPKD) is diagnosed by ultrasound, CT scan, or MRI. The Ravine's diagnostic criteria for individuals who have a 50% risk of developing ADPKD type 1 include:

- At least two unilateral (cysts in one kidney) or bilateral (cysts in both kidneys) cysts in individuals who are younger than age 30 for individuals with a positive family history of ADPK. Individuals with a negative family history of ADPKD need at least 5 cysts.
- At least two cysts in each kidney in individuals who are between 30 and 59 years for individuals with a positive family history of ADPK. Individuals with a negative family history of ADPKD need at least 5 cysts.
- At least four cysts in each kidney in individuals who are 60 years old or older for individuals with a positive family history of ADPK. Individuals with a negative family history of ADPKD need at least 8 cysts.

There are two genes known to be associated with ADPKD; *PKD1* and *PKD2*. *PKD1* is found in approximately 85 percent of individuals with ADPKD.

In human ADPKD cyst epithelial cells, tolvaptan inhibits AVP-stimulated *in vitro* cyst growth and chloride-dependent fluid secretion into cysts. In animal models, decreased cAMP concentrations were associated with decreases in the rate of growth of total kidney volume (TKV) and decreases in the rate of formation and enlargement of kidney cysts.

In 2013 the manufacturer and Food & Drug Administration (FDA) issued a warning on the potential of significant liver injury with the use of Samsca (tolvaptan) that was seen in patients with autosomal dominant polycystic kidney disease (ADPKD). The FDA safety announcement recommended limiting the duration of Samsca (tolvaptan) to no longer than 30 days and that it should not be used in patients with underlying liver disease.

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

Because of the risks of serious liver injury, Jynarque (tolvaptan) is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.

Definitions:

Mayo Clinic Classification (<http://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754>)

Class	Estimated kidney growth rate: yearly percentage increase	Risk for eGFR decline	Estimated eGFR slope (mL/min/1.73m ² per year: male)	Estimated eGFR slope (mL/min/1.73m ² per year: female)
1A	< 1.5	Low	- 0.23	0.03
1B	1.5- < 3	Intermediate	- 1.33	- 1.13
1C	3- < 4.5	High	- 2.33	- 2.43
1D	4.5- < 6	High	- 3.48	-3.29
1E	≥ 6	High	- 4.78	- 4.58

Classification only applies to patients with typical morphology of ADPKD as defined by diffuse bilateral cystic involvement of the kidneys.

In the absence of Cockcroft-Gault GFR, CKD-EPI >45 mL/min may be used, and in the absence of TKV, ultrasound kidney length >16.5 cm may be used.^{6,7}

Progression score for Polycystic Kidney Disease:

PROPKD	Points
Variable:	
Male	1
HTN before age 35 years	2
First urological event: Gross hematuria, cyst infections, and flank pain related to cysts	2
Mutation:	
<i>PKD2</i>	0
Non-truncating <i>PKD1</i>	2
Truncating <i>PKD1</i>	4

PROPKD Score	0	1	2	3	4	5	6	7	8	9
Risk of Progression to ESRD	Low Risk			Intermediate Risk			High Risk			
Median age for ESRD onset	70.6			56.9			49			

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

Five Stages of Kidney Disease:

- Stage 1 with normal or high GFR (GFR > 90 mL/min)
 - Stage 2 Mild CKD (GFR = 60-89 mL/min)
 - Stage 3A Moderate CKD (GFR = 45-59 mL/min)
 - Stage 3B Moderate CKD (GFR = 30-44 mL/min)
 - Stage 4 Severe CKD (GFR = 15-29 mL/min)
 - Stage 5 End Stage CKD (GFR <15 mL/min)
-

Resources:

Samsca (tolvaptan) Package Insert, revised by manufacturer 05-2019, accessed 06-19-20 at DailyMed

Jynarque (tolvaptan) Package Insert, revised by manufacturer 01-2020, accessed 06-19-20 at DailyMed

Torres VE, Bennett WM. Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis. In: UpToDate, Motwani S (Ed), UpToDate, Waltham, MA.: UpToDate Inc. <http://uptodate.com> (Accessed on June 19, 2020.)

Chapman AB, Rahbari-Oskoui FF, Bennett WM. Autosomal dominant polycystic kidney disease (ADPKD): Treatment. In: UpToDate, Perrone RD (Ed), UpToDate, Waltham, MA.: UpToDate Inc. <http://uptodate.com> (Accessed on June 19, 2020.)

Sterns R. Overview of the treatment of hyponatremia in adults. In: UpToDate, Forman JP (Ed), UpToDate, Waltham, MA.: UpToDate Inc. <http://uptodate.com> (Accessed on June 19, 2020.)

Sterns R. Treatment of hyponatremia: Syndrome of Inappropriate antidiuretic hormone secretion (SIADH) and reset osmotate. In: UpToDate, Emmett M (Ed), UpToDate, Waltham, MA.: UpToDate Inc. <http://uptodate.com> (Accessed on June 19, 2020.)

FDA Drug Safety Communications: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. Safety announcement April 30, 2013 UCM350084.

UpToDate: Treatment of autosomal dominant polycystic kidney disease. Current through Jun 2019

UpToDate: Hypertension in autosomal dominant polycystic kidney disease. Current through Jun 2019

UpToDate: Diagnosis and screening for autosomal dominant polycystic kidney disease. Current through Jun 2019

UpToDate: Overview of the treatment of hyponatremia in adults. Current through Jun 2019

Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1(1):148-157.

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 8/20/2020
LAST CRITERIA REVISION DATE: 8/20/2020
ARCHIVE DATE:

JYNARQUE™ (tolvaptan) oral
SAMSCA® (tolvaptan) oral
Tolvaptan oral

Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. *J Am Soc Nephrol*. 2015;26(1):160-172.

Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. *Kidney Int*. 2015; 88(1):146–151. doi:10.1038/ki.2015.71

Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol* 2016; 27: 942–951, doi: 10.1681/ASN.2015010016

Grantham JJ, Torres VE. The importance of total kidney volume in evaluating progression of polycystic kidney disease. *Nat Rev Nephrol*. 2016;12(11):667-677.

Soroka S, Alam A, Bevilacqua M, et al. Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a Canadian expert consensus. *Can J Kidney Health Dis*. 2017;4:2054358117695784. doi:10.1177/2054358117695784

Yu ASL, Shen C, Landsittel DP, et al; for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease. *Kidney Int*. 2018;93(3):691-699.

Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol* 2018;13: 1765–1776, doi: <https://doi.org/10.2215/CJN.03960318>
